A Randomized Study to Investigate the Efficacy and Safety of qw or q3w Trastuzumab, Paclitaxel and Carboplatin in Patients With IIB-IIIB HER2 Positive Breast Cancer
Overview
- Phase
- Phase 2
- Intervention
- Trastuzumab QW, Trastuzumab Q3W
- Conditions
- Breast Cancer
- Sponsor
- Fudan University
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Primary Endpoint is efficacy. To compare the efficacy in terms of the pathological complete response rate (pCR) to preoperative administration of qw or q3w Paclitaxel, Carboplatin and Trastuzumab (PCH).
- Last Updated
- 15 years ago
Overview
Brief Summary
To compare the efficacy in terms of the pathological complete response rate (pCR) to preoperative administration of qw or q3w Paclitaxel, Carboplatin and Trastuzumab (PCH)
Detailed Description
Currently Herceptin has moved to Neoadjuvant treatment combined with chemotherapy. Paclitaxel and Carboplatin are two of the best partners with high pCR. The significant efficacy and good safety profile of Herceptin® combination with taxane as adjuvant treatment on EBC are accepted; 1 year of Herceptin as adjuvant treatment is one standard therapy. This study is one small Phase II trial to explore the efficacy and safety of QW and Q3W of PCH as Neoadjuvant treatment, we only plan 60 pts and the trend of the two curves is anticipated
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women aged equals to or more than 18 years and no more than 70 years with life expectancy more than 12 months
- •Histologically confirmed invasive breast cancer (excluding inflammatory breast cancer) by core needle biopsy, T2N1 or local advanced breast cancer, with no evidence of metastasis
- •HER2 positive confirmed by FISH/CISH+ or IHC 3+
- •With no history of cancer other than in situ uterine cervix cancer or skin basal cell carcinoma
- •Adequate hematopoietic function: Neutrophil larger than 1.5\*109/L; Hb larger than 100g/L; PLT larger than 100\*109/L
- •Adequate hepatic and renal function
- •serum AST less than 60U/L
- •Total bilirubin less than 1.5 ULN
- •serum creatinine less than 110umol/L
- •BUN less than 7.1mmol/L
Exclusion Criteria
- •Prior systemic or loco-regional treatment of breast cancer, including chemotherapy
- •Metastatic breast cancer
- •Patients with medical conditions that renders them intolerant to neoadjuvant therapy and related treatment, including uncontrolled pulmonary disease, Diabetes Mellitus, severe infection, active peptic ulcer, Coagulation disorder, connective tissue disease or myelo-suppressive disease
- •History of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (Systolic BP more than 180mmHg or Diastolic BP more than 100mmHg）
- •grade 1 peripheral neuropathy from any cause
- •Patient is pregnant or nursing
- •Not willing to take pre-operative biopsy or neo-adjuvant therapy
- •Patients with psychiatric disorder or other disease leading to incompliance to the therapy
- •Known hypersensitivity to any ingredient of the regimen
- •Treatment with any investigational drug within 30 days before the beginning of treatment with study drug
Arms & Interventions
Trastuzumab QW
Arm A: Trastuzumab 2mg/kg, d1; qw (loading dose 4mg/kg wk1) Paclitaxel 80mg/m2,. d1; qw Carboplatin AUC 2 d1, qw
Intervention: Trastuzumab QW, Trastuzumab Q3W
Trastuzumab Q3W
Arm B: Trastuzumab 6mg/kg, d1(loading dose 8mg/kg wk1) Paclitaxel 175mg/m2,. d1, q3w; Carboplatin AUC 6 ,. d1,q3w
Intervention: Trastuzumab QW, Trastuzumab Q3W
Outcomes
Primary Outcomes
Primary Endpoint is efficacy. To compare the efficacy in terms of the pathological complete response rate (pCR) to preoperative administration of qw or q3w Paclitaxel, Carboplatin and Trastuzumab (PCH).
Time Frame: 3 years from last patient randomized
Primary Endpoint is efficacy. To compare the efficacy in terms of the pathological complete response rate (pCR) to preoperative administration of qw or q3w Paclitaxel, Carboplatin and Trastuzumab (PCH). The primary efficacy variable is the rate of pathological complete response (pCR). Time to recurrence will be measured as the time from when the patient was randomized to the time the patient is first recorded as having disease recurrence or the date of death if the patient dies due to causes other than disease recurrence.